Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tiny estradiol patch boost brain speed in turner syndrome?

NCT ID NCT07784582

Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study tests whether ultra-low dose estradiol patches, started between ages 8 and 11.5, are safe and may improve thinking speed and short-term memory in girls with Turner syndrome who have ovarian failure. Participants wear a small fraction of a standard patch, changed weekly for 6 months. The trial measures changes in processing speed and working memory, along with physical signs of puberty and hormone levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultra-low dose estradiol transdermal patch (1/8th of a 0.025 mg/24-hour patch, applied weekly)
What this could lead to
If it works, this could point toward a safe way to start hormone therapy in young girls with Turner syndrome, potentially improving their cognitive function and easing the transition to puberty.
What could go wrong
This is a small, early-phase study with only 15 participants, so results may not apply broadly. The ultra-low dose may not be enough to produce meaningful changes, and there are potential risks from hormone therapy, though the dose is designed to be minimal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 12 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Female, aged 8 years up to 11 y and 180 days with karyotype confirmed Turner syndrome 4. FSH result\> 10miu/mL in the past 12 months. Since variability in FSH is not uncommon, a single measure of FSH \>10mIU/mL in the past calendar year will be deemed sufficient for inclusion into the study even if repeat measures may be under 10mIU/mL. 5. Ability to take the transdermal estradiol medication and be willing to adhere to the treatment regimen 6. Ability to complete the primary endpoint testing in English. Non-English speakers may be recruited if the participant is capable of performing the English version of the tests. Exclusion Criteria: 1. Spontaneous thelarche with breast Tanner stage 3 or more, spontaneous menarche or history of abnormal uterine bleeding. 2. Previous estrogen exposure 3. Cognitive impairment is severe enough to prevent assessment of the primary outcome measures. 4. Untreated hypothyroidism or celiac disease: Individuals may be recruited if on treatment and stable medication dose in past 3 months. 5. Subjects known to have Y-chromosome material unless they have undergone gonadectomy and have fully external female genitalia 6. History of any type of malignancy 7. History of a known clotting disorder/deep venous thrombosis 8. Any clinically significant abnormality as determined by the principal investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary ovarian insufficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ovarian failure Turner syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary ovarian insufficiency Turner syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Children's National Hospital

    Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.